Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV-16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Vaccine Immunol
Main Authors: Apter, Dan, Wheeler, Cosette M., Paavonen, Jorma, Castellsagué, Xavier, Garland, Suzanne M., Skinner, S. Rachel, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Kitchener, Henry C., Teixeira, Julio C., Jaisamrarn, Unnop, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y., Schwarz, Tino F., Poppe, Willy A. J., Bosch, F. Xavier, Mindel, Adrian, de Sutter, Philippe, Hardt, Karin, Zahaf, Toufik, Descamps, Dominique, Struyf, Frank, Lehtinen, Matti, Dubin, Gary
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2015
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4375348/
https://ncbi.nlm.nih.gov/pubmed/25651922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00591-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados